Last reviewed · How we verify
Conventional low dose thromboprophylaxis
Conventional low-dose thromboprophylaxis prevents blood clot formation by inhibiting coagulation cascade factors, typically using anticoagulants at reduced doses for prevention rather than treatment.
Conventional low-dose thromboprophylaxis prevents blood clot formation by inhibiting coagulation cascade factors, typically using anticoagulants at reduced doses for prevention rather than treatment. Used for Thromboprophylaxis in surgical patients, Thromboprophylaxis in orthopedic surgery patients, Thromboprophylaxis in medical patients at risk for venous thromboembolism.
At a glance
| Generic name | Conventional low dose thromboprophylaxis |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Anticoagulant |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This approach uses standard anticoagulant agents (such as unfractionated heparin, low-molecular-weight heparin, or warfarin) at lower doses than those used for therapeutic anticoagulation. The reduced dosing is designed to prevent thrombotic events in high-risk patients while minimizing bleeding complications. It is commonly employed in surgical, orthopedic, and medical settings to reduce venous thromboembolism risk.
Approved indications
- Thromboprophylaxis in surgical patients
- Thromboprophylaxis in orthopedic surgery patients
- Thromboprophylaxis in medical patients at risk for venous thromboembolism
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
Key clinical trials
- Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional low dose thromboprophylaxis CI brief — competitive landscape report
- Conventional low dose thromboprophylaxis updates RSS · CI watch RSS
- UMC Utrecht portfolio CI